lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
== History == The varicella-zoster vaccine is made from the Oka/Merck strain of live attenuated varicella virus. The Oka virus was initially obtained from a child with natural varicella, introduced into human embryonic lung cell cultures, adapted to and propagated in embryonic guinea pig cell cultures, and finally propagated in a human diploid cell line originally derived from fetal tissues (WI-38). Takahashi and his colleagues used the Oka strain to develop a live attenuated varicella vaccine in Japan in the early 1970s. This strain was further developed by pharmaceutical companies such as Merck & Co. and GlaxoSmithKline. American vaccinologist Maurice Hilleman's team at Merck then used the Oka strain to prepare a chickenpox vaccine in 1981. Japan was among the first countries to vaccinate for chickenpox. The vaccine developed by Hilleman was first licensed in the United States in 1995. Routine vaccination against varicella zoster virus is also performed in the United States, and the incidence of chickenpox has been dramatically reduced there (from four million cases per year in the pre-vaccine era to approximately 390,000 cases per year as of 2014). As of 2019, standalone varicella vaccines are available in all 27 European Union member countries, and 16 countries also offer a combined measles, mumps, rubella, and varicella vaccine (MMRV).
=== Vacation food === Vacation foods, also known as "food blocks" (or "weekend blocks" for smaller versions), are designed to be placed inside the aquarium to forgo feeding while the owner is absent. These blocks release small amounts of food as they dissolve. Food blocks can be a good choice for smaller tropical fish, but can pollute the water if the tank is neglected for too long.
The Netherlands is the world's main producer of commercial tulip plants, producing as many as 3 billion bulbs annually, the majority for export. "Unlike many flower species, tulips do not produce nectar to entice insect pollination. Instead, tulips rely on wind and land animals to move their pollen between reproductive organs. Because they are self-pollinating, they do not need the pollen to move several feet to another plant but only within their blossoms." Tulips can be propagated through bulb offsets, seeds or micropropagation. Offsets and tissue culture methods are means of asexual propagation for producing genetic clones of the parent plant, which maintains cultivar genetic integrity. Seeds are most often used to propagate species and subspecies or to create new hybrids. Many tulip species can cross-pollinate with each other, and when wild tulip populations overlap geographically with other tulip species or subspecies, they often hybridise and create mixed populations. Most commercial tulip cultivars are complex hybrids, and often sterile. Offsets require a year or more of growth before plants are large enough to flower. Tulips grown from seeds often need five to eight years before plants are of flowering size. To prevent cross-pollination, increase the growth rate of bulbs and increase the vigour and size of offsets, the flower and stems of a field of commercial tulips are usually topped using large tractor-mounted mowing heads. The same goals can be achieved by a private gardener by clipping the stem and flower of an individual specimen.
Sources: en.wikipedia.org
=== 1979 === January 1: The United States and China normalize diplomatic relations. January 7: Vietnam deposes the Khmer Rouge and installs a pro-Vietnam, pro-Soviet government known as the People's Republic of Kampuchea. January 16: The Iranian Revolution ousts the pro-Western Shah, Mohammed Reza Pahlavi, and installs a theocracy under Grand Ayatollah Ruhollah Khomeini. The Central Treaty Organization dissolves as a result. February 17: Sino-Vietnamese War, China launches a punitive attack on Vietnam to punish it for invading Cambodia February 22: Saint Lucia becomes independent from the UK. February 24: A war broke out between Yemen Arab Republic and South Yemen. May 4: Margaret Thatcher is elected Prime Minister of the United Kingdom, becoming the first female to lead a major Western democracy. May 9: Civil war breaks out in El Salvador between Marxist-led insurgents and the U.S.-backed government. June 2: Pope John Paul II begins his first pastoral visit to his native Poland. June 18: U.S. President Jimmy Carter and Soviet leader Leonid Brezhnev sign the SALT II agreement, outlining limitations and guidelines for nuclear weapons. July 3: President Carter signs the first directive for financial aid to opponents of the pro-Soviet regime in Kabul, Afghanistan. July 16: Saddam Hussein becomes President of Iraq after Ahmed Hassan al-Bakr steps down. July 17: Marxist-led Sandinista revolutionaries overthrow the U.S.-backed Somoza dictatorship in Nicaragua. The Contra insurgency begins shortly thereafter.
On March 1, 2013, Governor Rick Snyder announced that the state would be assuming financial control of the city. A team was chosen to review the city's finances and determine whether the appointment of an emergency manager was warranted. Two weeks later, the state's Local Emergency Financial Assistance Loan Board (ELB) appointed an emergency financial manager, Kevyn Orr. Orr released his first report in mid-May. The results were generally negative regarding Detroit's financial health. The report said that Detroit is "clearly insolvent on a cash flow basis." The report said that Detroit would finish its current budget year with a $162 million cash-flow shortfall and that the projected budget deficit was expected to reach $386 million in less than two months. The report said that costs for retiree benefits were eating up a third of Detroit's budget and that public services were suffering as Detroit's revenues and population shrink each year. The report was not intended to offer a complete blueprint for Orr's plans for fixing the crisis; more details about those plans were expected to emerge within a few months. After several months of negotiations, Orr was ultimately unable to come to a deal with Detroit's creditors, unions, and pension boards and therefore filed for Chapter 9 bankruptcy protection in the Eastern District of Michigan U.S. Bankruptcy Court on July 18, 2013, the largest U.S. city ever to do so, with outstanding financial obligations to more than 100,000 creditors totaling approximately $18.5 billion. On December 10, 2014, Detroit successfully exited bankruptcy.
==== Fistula formation and gallstone ileus ==== The inflammation of cholecystitis can lead to adhesions between the gallbladder and other parts of the gastrointestinal tract, most commonly the duodenum. These adhesions can lead to the formation of direct connections between the gallbladder and gastrointestinal tract, called fistulas. With these direct connections, gallstones can pass from the gallbladder to the intestines. Gallstones can get trapped in the gastrointestinal tract, most commonly at the connection between the small and large intestines (ileocecal valve). When a gallstone gets trapped, it can lead to an intestinal obstruction, called gallstone ileus, leading to abdominal pain, vomiting, constipation, and abdominal distension.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.